Search - tctmd.com

Displaying 381 - 400 of 1510

Sort: Relevancy | Date

Presentation TVT 2021

Early neo2 Registry. Full Core-lab Results of TAVI With the New Acurate neo2 Valve

Presenter: Andreas Ruck

July 20, 2021

Presentation TVT 2021

The PARTNER 3 Bicuspid Registry for SAPIEN 3 Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk

Presenter: Mathew Williams

July 20, 2021

Presentation TVT 2021

Comparison of 1-Year Outcomes After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Severe Bicuspid and Tricuspid Aortic Valve Stenosis

Presenter: John Forrest

July 20, 2021

Presentation TVT 2021

MASTER CLASS #1: Advanced Bioprosthetic Valve Failure Treated With TAVR

Presenter: John Webb

July 20, 2021

News Conference News TVT 2020

Stroke in TAVR: Full Impact of Embolic Devices, Anticoagulants, Technique Remain Unclear

Todd Neale

June 25, 2020

News Conference News TVT 2020

Device Explants After TAVR Rare but Risky

Michael O'Riordan

June 24, 2020

News Conference News TVT 2020

Real-world, Low-risk Patients Fare Well With Self-Expanding Evolut PRO

Shelley Wood

June 24, 2020

News Conference News TVT 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Michael O'Riordan

June 23, 2020

News Conference News TVT 2020

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

Michael O'Riordan

June 22, 2020

Presentation TVT 2020

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-risk Patients: A Propensity-Matched Analysis of 5-year Outcomes

Presenter: Susheel K. Kodali

June 21, 2020

Presentation TVT 2020

Outcomes of Surgical Explantation of TAVR– A Population-Based, Nationally-Representative Analysis

Presenter: Tsuyoshi Kaneko

June 21, 2020

Presentation TVT 2020

First Prospective Randomized Clinical Trial Assessing Incidence of Reduced Leaflet Motion and its Clinical Impact Following Transcatheter Aortic Valve Implantation

Presenter: Hasan Jilaihawi

June 21, 2020

Presentation TVT 2020

Valve-in-Surgical Valve with SAPIEN 3 for Transcatheter Aortic Valve Replacement:Propensity-Matched Analyses of Real World Data Based on the STS Predicted Risk of Mortality

Presenter: Tsuyoshi Kaneko

June 20, 2020

Presentation TVT 2020

Transcatheter Aortic Valve Replacement with Self-Expandable Supra Annular Valves for Failed Surgical Bioprostheses: Insights From the TVT Registry

Presenter: Guilherme F. Attizzani

June 20, 2020

Presentation TVT 2020

Transcatheter Aortic Valve Replacement using an Evolut PRO Bioprosthesis in Low Risk Patients with Aortic Stenosis

Presenter: Bruce Rutkin

June 20, 2020

Presentation TVT 2020

Real-world experience with the SAPIEN 3 Ultra TAVR: A propensity matched analysis from the United States

Presenter: Tamim Nazif

June 20, 2020

News Conference News TVT 2020

Newer TAVR Devices Reassure in Failed Surgical Valves

Shelley Wood

June 20, 2020

News Conference News TVT 2020

Skipping Predilatation in Low-risk TAVR Patients Does Not Mar Outcomes

L.A. McKeown

June 19, 2020

News Conference News TVT 2019

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Michael O'Riordan

June 20, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

Advertisement

Early neo2 Registry. Full Core-lab Results of TAVI With the New Acurate neo2 Valve

The PARTNER 3 Bicuspid Registry for SAPIEN 3 Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk

Comparison of 1-Year Outcomes After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Severe Bicuspid and Tricuspid Aortic Valve Stenosis

MASTER CLASS #1: Advanced Bioprosthetic Valve Failure Treated With TAVR

Stroke in TAVR: Full Impact of Embolic Devices, Anticoagulants, Technique Remain Unclear

Device Explants After TAVR Rare but Risky

Real-world, Low-risk Patients Fare Well With Self-Expanding Evolut PRO

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-risk Patients: A Propensity-Matched Analysis of 5-year Outcomes

Outcomes of Surgical Explantation of TAVR– A Population-Based, Nationally-Representative Analysis

First Prospective Randomized Clinical Trial Assessing Incidence of Reduced Leaflet Motion and its Clinical Impact Following Transcatheter Aortic Valve Implantation

Valve-in-Surgical Valve with SAPIEN 3 for Transcatheter Aortic Valve Replacement:Propensity-Matched Analyses of Real World Data Based on the STS Predicted Risk of Mortality

Transcatheter Aortic Valve Replacement with Self-Expandable Supra Annular Valves for Failed Surgical Bioprostheses: Insights From the TVT Registry

Transcatheter Aortic Valve Replacement using an Evolut PRO Bioprosthesis in Low Risk Patients with Aortic Stenosis

Real-world experience with the SAPIEN 3 Ultra TAVR: A propensity matched analysis from the United States

Newer TAVR Devices Reassure in Failed Surgical Valves

Skipping Predilatation in Low-risk TAVR Patients Does Not Mar Outcomes

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content